Global Hematologic Malignancies Testing market was estimated at USD 3.3 billion in 2023 and is expected to grow up to USD 13.6 billion by 2030, registering a CAGR of 14.7% during the forecast period ranging between 2025 and 2030.
Global Hematologic Malignancies Testing market was estimated at USD 3.3 billion in 2023 and is expected to grow up to USD 13.6 billion by 2030, registering a CAGR of 14.7% during the forecast period ranging between 2025 and 2030.
Hematologic malignancies are the specific types of blood cancers such as myeloma, leukemia, and lymphoma. These diseases need proper monitoring and effective detection of the treatment, and these need advanced diagnostic techniques, such as hematologic malignancies testing. These tests help in determining the presence and type of blood cancers. The healthcare professionals create tailor treatment plans that are based on the severity of the disease. Due to the rising prevalence of cancer on a global scale, the demand for such testing is expected to grow during the forecast period 2025 - 2030. Despite the significant growth potential, the market hindrances like high cost of advanced tests, the strict regulatory frameworks which restricts widespread adoption and growth of the market. Significant growth in the research healthcare and activities investments along with the growing government initiatives in developing economies offer significant opportunities for market growth.
Browse 78 market data Tables and 45 Figures spread through 198 Pages and in-depth TOC on Global Hematologic Malignancies Testing market By Test Types (Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics and Others), By Application (Leukemia, Lymphoma, Myeloma and Others), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy and Other Therapies), By End User (Hospitals, Diagnostic Labs, Academic and Research Institutions and Others) and By Geography (North America, Europe and Asia Pacific) - Global Forecast from 2025 to 2030.
Global Hematologic Malignancies Testing Market Segmentation and Key Players
|
Segment / Key Players |
Categorization |
|
Test Types |
Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing and Others |
|
Technology |
Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics and Others |
|
Application |
Leukemia, Lymphoma, Myeloma and Others |
|
Therapy |
Chemotherapy, Immunotherapy, Targeted Therapy and Other Therapies |
|
End User |
Hospitals, Diagnostic Labs, Academic and Research Institutions and Others |
|
Key Players |
GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, Merck & Co. Inc., Johnson & Johnson Private Limited, Cipla Inc., Novartis AG, AstraZeneca, Abbott, LEO Pharma A/S, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Lupin, Hikma Pharmaceuticals, Fresenius Kabi AG |
By test type, molecular testing dominate the global hematologic malignancies testing market
The global Hematologic Malignancies Testing market is segmented by test type into complete blood count (CBC), flow cytometry, molecular testing, genetic testing, and others. Among all these segments, the molecular testing category holds the largest market share and is expected to dominate the market during the forecast period due to its high accuracy and efficiency in detecting genetic mutations related to blood cancers. Furthermore, within this particular segment, the Next-Generation Sequencing (NGS) is more likely to drive growth due to its ability to provide more comprehensive and faster results. The flow cytometry segment is also projected to grow due to its higher adoption in clinical laboratories and efficiency in diagnosing leukemia and lymphoma.
"North America is anticipated to register the fastest CAGR during the forecast period, i.e., 2025-2030 in the global global hematologic malignancies testing market.”
North America dominates the global Hematologic Malignancies Testing market currently mainly due to higher government funding for cancer research, improved healthcare systems, and the presence of key market players.
Some of the key players in this market are GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, Merck & Co. Inc., Johnson & Johnson Private Limited, Cipla Inc., Novartis AG, AstraZeneca, Abbott, LEO Pharma A/S, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Lupin, Hikma Pharmaceuticals, Fresenius Kabi AG,
Recent Developments of Key Players
Merck & Co. Inc. has acquired Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to USD 1.3 billion.
The global hematologic malignancies testing market report offers a comprehensive market segmentation analysis along with estimation for the forecast period 2025–2030.
Global Hematologic Malignancies Testing Market coverage (By Value)
- Test Types Insight and Forecast 2025 - 2030
- Complete Blood Count (CBC)
- Flow Cytometry
- Molecular Testing
- Genetic Testing
- Others
- Technology Insight and Forecast 2025 - 2030
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Immunohisto Chemistry (IHC)
- Cytogenetics
- Others
- Application Insight and Forecast 2025 - 2030
- Leukemia
- Lymphoma
- Myeloma
- Others
- Therapy Insight and Forecast 2025 - 2030
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Other Therapies
- End User Insight and Forecast 2025 - 2030
- Hospitals
- Diagnostic Labs
- Academic and Research Institutions
- Others
Geographical Segmentation
Global Hematologic Malignancies Testing Market by Region
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- North America
- The U.S.
- Canada
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Middle East & Africa
- GCC
- South
- Africa
- Rest of Middle East & Africa